Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV F vaccine with aluminum phosphate adjuvant
- Development stage
- Discontinued
- Lead developer
- Novavax
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
The RSV F vaccine with aluminum phosphate adjuvant is an investigational recombinant protein nanoparticle vaccine developed by Novavax for the prevention of respiratory syncytial virus (RSV) infection. The vaccine is composed of a purified, near-full-length RSV fusion (F) glycoprotein that forms stable protein-detergent nanoparticles, formulated with aluminum phosphate (AdjuPhos) as an adjuvant to enhance immunogenicity. It targets the RSV F protein, a critical surface glycoprotein that mediates viral attachment and membrane fusion. The vaccine was evaluated in multiple clinical settings, including older adults and maternal immunization (under the brand name ResVax). Although Phase 2 studies in older adults demonstrated robust antibody responses and a potential reduction in COPD-related hospitalizations, the vaccine failed to meet its primary efficacy endpoints in a large Phase 3 trial (Resolve) in older adults and a Phase 3 trial (Prepare) for maternal immunization.
- Brand names
- ResVax
- Other names
- RSV F nanoparticle vaccineRSV F recombinant protein vaccineRSV F vaccine with AdjuPhos
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on RSV F vaccine with aluminum phosphate adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV F vaccine with aluminum phosphate adjuvant.